You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than serovars of the genus Leptospira In the US there is increasing awareness of the importance of leptospirosis as the cause of disease among inner city populations military personnel and individuals ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Targeting STT3A and STT3B to Block Flavivirus Replication

    SBC: New England Discovery Partners, LLC            Topic: NIAID

    AbstractMosquito borne flaviviruses cause disease worldwidewith members such as dengue virusDENVZika virusZIKVand west nile virusWNVinfecting more thanmillion individuals annuallyThe availability of small molecule antivirals that reduce flavivirus infection therefore could have an immediate and substantial impact on public health programs that seek to improve outcomes for populations infected with ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Validation of a Diagnostic Test for Borrelia miyamotoi

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    ABSTRACT Borrelia miyamotoi is a tick transmitted spirochete recently shown to cause infection and disease in the United StatesEurope and AsiaA member of the relapsing fever group of Borreliathis pathogen has been proven to cause most commonly a nonspecificflu like illness with feverfatiguemyalgiaand headacheDisease can be particularly severe and involve the central nervous system in immunocomprom ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Development of the first thermolytic to suppress shivering and seizure

    SBC: BE COOL PHARMACEUTICS LLC            Topic: NHLBI

    Summary The temperature management market is expected to reach $billion byyet no pharmaceutical has yet been developed specifically for this marketAadenosineA ARagonists are well known to attenuate seizure and protect the brain from injurybut development of these drugs has been limited by side effects including hypothermiabradycardia and hypotensionInspired by our discoveries thatN cyclohexyl aden ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. A novel approach to treat non alcoholic steatohepatitis NASH

    SBC: MITOTHERAPEUTIX, LLC            Topic: 300

    Abstract The Specific Aim of this Phase I STTR proposal is to test the feasibility of treating non alcohol steatohepatitis NASH by increasing mitochondrial metabolism which is the main pathway for lipid catabolism in the liver NASH is a stage of non alcohol fatty liver disease NAFLD that has progressed to a pathological state NASH can lead to cirrhosis leading to liver failure or hepatocel ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Scaffold to Promote Skin Regeneration

    SBC: FirstString Research, Inc            Topic: NIAMS

    PROJECT SUMMARY Dermal scarring affects more than million people worldwide annually over million people are injured in motor vehicle accidents over million patients are severely burned and thousands of warriors are wounded in military blasts In severe burns more than of patients develop hypertrophic scar contraction which leads to hypertrophic scar contractures HSc HSc a ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    Polo like kinase PLK is a central player in regulating entry into and progression through mitosis Many studies have validated PLK as an anti tumor drug target and its inhibition is potently anti proliferative to cancer cells However recent data suggests that there are two major disadvantages of the conventional approach to blocking the kinase activity of PLK First both general kinome ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government